CN1049117C - Tablet for preventing and curing migraine - Google Patents
Tablet for preventing and curing migraine Download PDFInfo
- Publication number
- CN1049117C CN1049117C CN94116067A CN94116067A CN1049117C CN 1049117 C CN1049117 C CN 1049117C CN 94116067 A CN94116067 A CN 94116067A CN 94116067 A CN94116067 A CN 94116067A CN 1049117 C CN1049117 C CN 1049117C
- Authority
- CN
- China
- Prior art keywords
- migraine
- tablet
- preventing
- caffeine
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a tablet for preventing and treating migraine, which mainly comprises caffeine, propranolol hydrochloride and phenytoin sodium, wherein each tablet comprises 60 to 100 mg of caffeine, 8 to 150 mg of propranolol hydrochloride and 80 to 150 mg of phenytoin sodium. The present invention can resist platelet aggregation, prevent intracranial artery spasm, increase extracranial artery resistance and prevent intracranial, and therefore, migraine can be relieved. The results of clinical tests indicate that the total effective rate reaches more than 93%, and the present invention is a solid coated tablet for preventing and treating migraine.
Description
The present invention relates to a kind of treatment migraine class medicine, it is a kind ofly to have prevention and treat migrainous sugar cube garment piece.
Migraine is commonly encountered diseases and frequently-occurring disease, average attack rate 5-10%.Particularly in China, along with dwindling of differentials between town and country, the accelerating of people's lives rhythm, prevalence can be growing on and on.Treat migrainous medicine at present, as: Ergotamine and ergotin analog derivative, pizotifen, thiophene pyridine in heptan, Propranolol, aspirin and other NSAID (non-steroidal anti-inflammatory drug), clonidine, nimodipine stable and that occur in recent years and flunarizine etc.These Drug therapy migraine all in various degree to exist effective percentage low or the shortcoming of certain toxic and side effects arranged.But the compound preparation ergotamine and caffeine tablet also is restricted because of the side effect of prolonged application intoxicating and drug dependence or addiction.
The purpose of this invention is to provide a kind of effective percentage height, toxicity is low, and side effect is little, has certain safety and treats migrainous medicine.
Main caffeine, propranolol hydrochloride, the phenytoin Sodium of containing of the present invention is the 90.0-110.0% of labelled amount.
Its prescription: caffeine 60-100mg
Propranolol hydrochloride 8-15mg
Phenytoin Sodium 80-150mg
20% starch slurry 30-55mg
Magnesium stearate 5-10mg
Make 1
Preparation method: adopt the caffeine that meets " Chinese Pharmacopoeia " 8 or five years version regulations, propranolol hydrochloride, phenytoin Sodium take by weighing supplementary material successively, sieve respectively, mix homogeneously is made soft material with 20% starch slurry as binding agent, granulates by 10 nylon mesh, oven dry is 4-6 hour below 60 degree Celsius, natural cooling by 14 mesh sieve granulate, adds the magnesium stearate mix homogeneously again, tabletting, coating is made.
Effect to each component reaches selected being described as follows below:
1, coffee is because central stimulants is share the treatment migraine with Ergotamine for many years, and its migraine effect is relevant to cerebrovascular contraction with it.It can reach the migrainous effect of treatment by anticoagulant.
2, the general bitter edible plant Luo Er of hydrochloric acid is the beta receptor blocker, and its migraine mechanism prevents that with its beta receptor blocking-up the outer vasodilation of cranium is relevant.But heavy dose of Propranolol anticoagulant reduces the 5-HT receptor, and these effects show the migraine effect with preventing intracranial from shrinking relevant.
3, phenytoin Sodium is the sick medicine of epilepsy, also is used for the treatment of migraine, and is relevant with its membrane stabilizing action.
Pathogenesis of migraine mainly is because platelet function abnormality discharges a large amount of 5-HT, cause that entocranial artery shrinks, so that cerebral hypoxia, angiogenic substances such as histamine and Kallidin I are increased, 5-HT is destroyed rapidly simultaneously, thereby makes the outer arteriectasia of cranium cause migraine.Therefore, all energy antagonism 5-HT function of receptors, the medicine that increases outer tremulous pulse resistance of cranium or antiplatelet aggregation all has the effect of alleviation and prevention of migraine outbreak.
Contained caffeine, propranolol hydrochloride, the phenytoin Sodium of the present invention all can influence some link of migraine morbidity, so share " the migraine sheet " of composition, the three aspect treatment, can produce following beneficial effect: 1, antiplatelet aggregative activity, three medicines have synergism, thereby prevent the entocranial artery spasm; 2, prevent the outer arteriectasia aspect of cranium, caffeine and propranolol hydrochloride have synergism, thereby increase the outer tremulous pulse resistance of cranium, alleviate migraine; 3, membrane stabilizing action, propranolol hydrochloride and phenytoin Sodium have synergism, and the pain sensation due to the retardance vasodilation is conducted strong effect; 4, the central inhibitory action of propranolol hydrochloride and phenytoin Sodium can be weakened by caffeine; 5, the used dosage of migraine sheet is significantly less than each prescription dosage, each oral 1 of migraine sheet, every optimum content is caffeine 70mg, hydrochloric acid naphthalene Luo Er 10mg, phenytoin Sodium 100mg, and their common dose is respectively 100mg-300mg, 80mg-120mg and 100mg-200mg, because the used dosage of migraine sheet is little, so side effect is lowered greatly.The present invention shows that through the clinic trial result total effective rate reaches more than 93%.
Migraine sheet and pizotifen sheet and placebo tablet see Table through clinic trial curative effect comparative result
Table one: comparative result is imitated in three medications
Three kinds of drug side effectes relatively see Table two
| Nomenclature of drug | The example number | Cure | Produce effects | Effectively | Invalid | ||||
| The example number | ％ | The example number | ％ | The example number | ％ | The example number | ％ | ||
| The migraine sheet | 32 | 8 | 25 | 13 | 40.62 | 9 | 28.13 | 2 | 8.25 |
| The pizotifen sheet | 30 | 2 | 6.67 | 7 | 23.33 | 11 | 36.67 | 10 | 33.33 |
| Placebo tablet | 31 | 0 | 0 | 3 | 9.68 | 8 | 25.80 | 20 | 64.22 |
Table two: three kinds of drug side effect comparative results
| Nomenclature of drug | The example number | Have no side effect | Dizzy | Xerostomia | Dyskoimesis | Asthenia | Gastrointestinal tract does not relax | Other side effect | |||||||
| The example number | ％ | The example number | ％ | The example number | ％ | The example number | ％ | The example number | ％ | The example number | ％ | The example number | ％ | ||
| The migraine sheet | 32 | 26 | 81.25 | 1 | 3.12 | 0 | 0 | 3 | 9.3 | 0 | 0 | 1 | 3.12 | 1 | 3.12 |
| Benzene miaow pyridine sheet | 30 | 20 | 66.68 | 3 | 10 | 1 | 3.33 | 1 | 3.33 | 3 | 10 | 1 | 3.33 | 1 | 3.33 |
| Placebo tablet | 31 | 28 | 90.31 | 1 | 3.23 | 0 | 3.23 | 1 | 3.23 | 1 | 3.23 | 0 | 0 | 0 | 0 |
Instantiation of the present invention is as follows:
Preferred example is: contain caffeine 70mg in 1, propranolol hydrochloride 10mg, phenytoin Sodium 100mg.
Claims (1)
1, a kind ofly prevent and treat migrainous migraine sheet, it is characterized by: it contains caffeine, propranolol hydrochloride and phenytoin Sodium, and the content of its 1 middle each component is respectively 60-100mg, 8-15mg and 80-150mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94116067A CN1049117C (en) | 1994-09-16 | 1994-09-16 | Tablet for preventing and curing migraine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94116067A CN1049117C (en) | 1994-09-16 | 1994-09-16 | Tablet for preventing and curing migraine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1129105A CN1129105A (en) | 1996-08-21 |
| CN1049117C true CN1049117C (en) | 2000-02-09 |
Family
ID=5037776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94116067A Expired - Lifetime CN1049117C (en) | 1994-09-16 | 1994-09-16 | Tablet for preventing and curing migraine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1049117C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| WO2004096228A1 (en) | 2003-04-25 | 2004-11-11 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
| CN102125522B (en) * | 2010-01-15 | 2013-01-16 | 复旦大学附属华山医院 | P-glycoprotein monoclonal antibody modified phenytoin targeting nanopreparation and preparation method thereof |
| CN103446156A (en) * | 2013-08-20 | 2013-12-18 | 云南农业大学 | Application of caffeine in preparing anticoagulation medicine |
-
1994
- 1994-09-16 CN CN94116067A patent/CN1049117C/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| 《当代结构药物全集》第一版 1993.1.1 王泽民主编，北京科技出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1129105A (en) | 1996-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60035870T2 (en) | COMBINATION THERAPY FOR WEIGHT REDUCTION AND FAT TREATMENT TREATMENT | |
| DE60004797T2 (en) | MEDICINAL PRODUCTS WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES CONTAINING ISOQUERCETINE AND ASCORBIC ACID | |
| DE69916629T2 (en) | TAUROLIDIN AND / OR TAURULTAM FOR TREATING INFECTIOUS ULCERA OR GASTRITIS | |
| CN1049117C (en) | Tablet for preventing and curing migraine | |
| DE69919003T2 (en) | ACETAMINOPHONE FORMULATION WITH EXTENDED RELEASE | |
| EP2378900A2 (en) | Food supplements based on pantothenic acid | |
| DE69903283T2 (en) | SYNERGISTIC COMPOSITION FOR THE TREATMENT OF CANCER CONTAINING INULIN AND AN ANTIQUE DRUG | |
| CN111905017A (en) | A kind of Chinese medicine composition and application of anti-Helicobacter pylori | |
| DE2715384C3 (en) | Medicines for diarrhea | |
| JPS6226229A (en) | Nervous cell differentiation promoter | |
| CN1056990C (en) | Composite pharmaceutics for curing dysentery | |
| CN1016141B (en) | Preparation method of novel sanguisorba officinalis preparation | |
| JPS59205321A (en) | Anthelmintic synergistical novel composition | |
| CN101185701A (en) | Chemical medicine and natural medicine composition for treating diabetes chronic complication and preparation method thereof | |
| JP4232461B2 (en) | Atopic dermatitis improving agent | |
| CN106924283A (en) | It is a kind of containing montmorillonite, the antidiarrheal pharmaceutical composition of medicinal carbon and preparation method and purposes | |
| DE202006001770U1 (en) | Use of activated carbon particles, preferably in the form of granules and pellets, for the production of medicaments for treating inflammatory diseases of stomach/intestinal tract diseases, e.g. diarrhea and enterocolitis | |
| CN1232681A (en) | Hog cholera treating medicine | |
| CN1389265A (en) | Composite Chinese medicine with health care function | |
| CN1274334C (en) | Combination of medication for relieving diarrhea, and preparation method | |
| CN1153583C (en) | Bone-setting pill 'Jiegudan' | |
| CN1257735A (en) | Medicine for treating constipation and its preparing process | |
| CN1278696C (en) | Pharmaceutical use of asafetida | |
| EP0129822A2 (en) | Pharmaceutical preparation with an anti-tumour activity | |
| CN1250236C (en) | The application of plant grass cotton total flavonoids in the preparation of antithrombotic drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HEBEI TIANCHENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHAO MINGYU Effective date: 20070105 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070105 Address after: Street traffic in Hebei province Cangzhou City Zhiqiang road 061000 Patentee after: Hebei Tiancheng Pharmaceutical Co., Ltd. Address before: 061001 Cangzhou new hospital of Hebei Province Patentee before: Zhao Mingyu |
|
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20140916 Granted publication date: 20000209 |